Page 93 - Eceptor News Today

In a recent study published in the journal Science Translational Medicine, researchers in the United States designed a bivalent coronavirus disease 2019 (COVID-19) vaccine on the messenger ribonucleic acid (mRNA) platform.

This study is led by Dr. Ruifu Yang, Dr. Zongmin Du (State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology) and Dr. Fan Bai (Biomedical Pioneering Innovation Center, School of Life Sciences, Peking University).

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

In a recent study posted to the bioRxiv* preprint server, researchers at the University of Tuebingen and Imperial College London assessed humoral and cellular immune responses elicited by the recombinant adenoviral vector (rAdVV)- and messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines.

In a recent study published in the journal PLoS Biology, researchers investigated the role of angiotensin-converting enzyme 2 (ACE2)-containing defensive exosomes, or 'defensosomes' against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib remain poorly understood. In this study, we demonstrated, for the first time, that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells.

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

The TIMP-1 protein levels in both tissues and blood have been repeatedly associated with a poor prognosis in lung cancers, but its role in this cancer process was, to date, unknown.

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology Congress 2022.

Starting twice daily flushing of the mucus-lined nasal cavity with a mild saline solution soon after testing positive for COVID-19 can significantly reduce hospitalization and death, investigators report.